Mycotopia Therapies Inc
For the period ended Dec 31, 2023. Filed Apr 23, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 23, 2024
AIBTStored price and day change unavailable
Contents
Item 101. Interactive Data File
| 101.INS | XBRL Instance Document | This filing. |
|---|---|---|
| 101.SCH | XBRL Taxonomy Extension Schema | This filing. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase | This filing. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase | This filing. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase | This filing. |
| * | All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. |
|---|---|
| ** | Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability. |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MYCOTOPIA THERAPIES, INC. | ||
| Date: April 19, 2024 | By: | /s/ Benjamin Kaplan |
|---|---|---|
| Benjamin Kaplan, | ||
| Chief Executive Officer (Principal Executive | ||
| Officer, Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.